Company Profile: Asuragen, a Bio-Techne Brand
Background
Asuragen, established in 2006 and headquartered in Austin, Texas, specializes in molecular diagnostics, focusing on genetic testing solutions for inherited disorders and precision oncology. In April 2021, Bio-Techne Corporation, a global life sciences company, acquired Asuragen for $215 million in cash, with potential additional payments of up to $105 million upon achieving certain milestones. This acquisition expanded Bio-Techne's portfolio, integrating Asuragen's expertise in genetic diagnostics and oncology testing.
Key Strategic Focus
Asuragen's strategic focus encompasses:
- Core Objectives: Developing and commercializing molecular diagnostic products that enhance patient care through accurate genetic testing.
- Areas of Specialization: Genetic testing solutions for inherited disorders, such as Fragile X syndrome, CFTR, and SMN1/2; precision oncology solutions addressing complex molecular challenges in cancers like chronic myeloid leukemia (CML) and solid tumors.
- Key Technologies Utilized: Proprietary chemistries compatible with widely available platforms, including PCR, qPCR, capillary electrophoresis, and next-generation sequencing instruments.
- Primary Markets Targeted: Clinical laboratories, hospitals, and research institutions globally, with a particular emphasis on markets in the United States, Europe, and the Asia-Pacific region.
Financials and Funding
In 2020, prior to its acquisition, Asuragen reported revenues exceeding $30 million. The acquisition by Bio-Techne in April 2021 for $215 million in cash, plus potential additional payments of up to $105 million upon achieving certain milestones, was financed through a combination of cash on hand and an existing revolving line of credit.
Pipeline Development
Asuragen's pipeline includes:
- Key Pipeline Candidates: AmplideX® Nanopore Carrier Plus Kit, a genetic testing panel for carrier screening research; ESR1 exoMutation assay, an exosome-based assay for assessing ESR1 mutations in breast cancer patients.
- Stages of Development: The AmplideX® Nanopore Carrier Plus Kit is in the development stage, with plans for launch in the near future. The ESR1 exoMutation assay was launched in December 2024.
- Target Conditions: The AmplideX® Nanopore Carrier Plus Kit targets complex genetic variants in carrier screening, while the ESR1 exoMutation assay focuses on detecting ESR1 mutations associated with resistance to endocrine therapy in breast cancer.
- Anticipated Milestones: The launch of the AmplideX® Nanopore Carrier Plus Kit is anticipated in the near future, aiming to address technical challenges in sequencing certain genes.
Technological Platform and Innovation
Asuragen's technological innovations include:
- Proprietary Technologies: AmplideX® PCR technology, enabling detection and analysis of complex genetic variants.
- Significant Scientific Methods: Exosome-based assays for liquid biopsy applications, facilitating non-invasive detection of genetic mutations.
Leadership Team
Asuragen's leadership includes:
- Matt McManus: Chief Executive Officer, leading Asuragen since its inception and overseeing its integration into Bio-Techne.
Competitor Profile
- Market Insights and Dynamics: The molecular diagnostics market is experiencing growth due to increasing demand for genetic testing in inherited disorders and oncology.
- Competitor Analysis: Key competitors include Thermo Fisher Scientific Inc., Danaher Corporation, and Abbott Laboratories, each offering a range of diagnostic products and services.
Strategic Collaborations and Partnerships
Asuragen has engaged in strategic collaborations, such as:
- Oxford Nanopore Technologies: Partnered to develop the AmplideX® Nanopore Carrier Plus Kit, combining long-range PCR and nanopore sequencing for carrier screening.
Operational Insights
Asuragen's integration into Bio-Techne has enhanced its operational capabilities, leveraging Bio-Techne's global distribution network and resources to expand market reach and accelerate product development.
Strategic Opportunities and Future Directions
Asuragen aims to:
- Expand Product Portfolio: Develop and commercialize additional diagnostic assays addressing unmet clinical needs.
- Enhance Global Presence: Leverage Bio-Techne's infrastructure to penetrate new international markets.
- Innovate Diagnostic Solutions: Continue advancing exosome-based assays and other innovative technologies to improve patient care.
Contact Information
- Official Website: Asuragen
- Social Media Profiles: LinkedIn
- Headquarters Location: Austin, Texas, USA
